Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC8935)

• Drug Name: Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 Drug Info
• Synonyms: PMID27321640-Compound-37
• Cross-matching ID: TTD Drug ID: DMC8935

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated potassium channel Kv11.1 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VESNARINONE	DMBKX3C	Cardiac failure	BD10-BD13	Approved	[2]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[3]
HP-184	DMNOMV2	Multiple sclerosis	8A40	Phase 2	[4]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[5]
ABT-229	DMN3S1B	Pain	MG30-MG3Z	Phase 2	[6]
ISOQUINE	DMR17YI	Malaria	1F40-1F45	Phase 1	[7]
Isoindoline derivative 5	DMIUTQW	N. A.	N. A.	Patented	[8]
Isoindoline derivative 3	DM2MYL9	N. A.	N. A.	Patented	[8]
Isoindoline derivative 4	DMP1NKI	N. A.	N. A.	Patented	[8]
Isoindoline derivative 2	DMTE0S3	N. A.	N. A.	Patented	[8]

Drug(s) Targeting Phosphodiesterase 2A (PDE2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[9]
CP-461	DMEYMTX	Inflammatory bowel disease	DD72	Phase 2	[10]
ND7001	DMUBTC6	Mood disorder	6A60-6E23	Phase 1	[11]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	DM4CSBD	N. A.	N. A.	Patented	[1]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2	DMS3ROL	N. A.	N. A.	Patented	[1]
Triazolo-pyridine derivative 5	DM1R205	N. A.	N. A.	Patented	[1]
PMID27321640-Compound-58	DM0NYK3	N. A.	N. A.	Patented	[1]
Triazolo-pyridine derivative 4	DM5ZQKS	N. A.	N. A.	Patented	[1]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3	DMZ61T8	N. A.	N. A.	Patented	[1]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4	DMKR5ZO	N. A.	N. A.	Patented	[1]

Drug(s) Targeting Phosphodiesterase 10A (PDE10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[9]
TAK-063	DMP1873	Schizophrenia	6A20	Phase 2	[12]
PF-02545920	DMJPE61	Huntington disease	8A01.10	Phase 2	[13]
OMS824	DMA4OGL	Huntington disease	8A01.10	Phase 2	[14]
Lu AF11167	DMJOYNZ	Schizophrenia	6A20	Phase 2	[15]
FRM-6308	DMNCOE1	Schizophrenia	6A20	Phase 1b	[16]
PBF-999	DMBSQH9	Huntington disease	8A01.10	Phase 1	[17]
RG7203	DMYX4NP	Schizophrenia	6A20	Phase 1	[18]
AMG 579	DMRMC7U	Schizophrenia	6A20	Phase 1	[19]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	DM4CSBD	N. A.	N. A.	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 10A (PDE10)	TTJW4LU	PDE10_HUMAN	Inhibitor	[1]
Phosphodiesterase 2A (PDE2A)	TTJGW1Z	PDE2A_HUMAN	Inhibitor	[1]
Voltage-gated potassium channel Kv11.1 (KCNH2)	TTQ6VDM	KCNH2_HUMAN	Inhibitor	[1]

References

• [1] Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
• [2] Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
• [3] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [4] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [5] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [6] 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
• [7] Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
• [8] The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
• [9] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [10] Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
• [11] Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212.
• [12] Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] New Drugs/Drug News. P T. 2013 November; 38(11): 667-672.
• [15] PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178.
• [16] Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2.
• [17] Clinical pipeline report, company report or official report of Palobiofarma.
• [18] Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013
• [19] Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41.